title: [Amplification of  γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
abstract: OBJECTIVE
  To investigate the amplification and cytotoxicity of γδ T cells in peripheral blood mononuclear cells (PBMCs) of healthy donors and osteosarcoma patients stimulated by zoledronate (Zol) and IL-2.
  
  
  METHODS
  PBMCs from healthy donors and osteosarcoma patients were stimulated with IL-2 and Zol+IL-2,  respectively. After 14-day culture,  the purity of γδ T cells was assessed by flow cytometry.  The cytotoxicity of γδ T cells against target cells was analyzed using a standard lactate dehydrogenase release assay with γδ T lymphocyte-sensitive Daudi cells,  γδ T lymphocyte-resistant Raji cells and human osteoblast cell line,  hFOB,  as the target cells.
  
  
  RESULTS
  After 2-week culture ex vivo of PBMCs from healthy donors and osteosarcoma patients,  compared with stimulation of IL-2,  Zol+IL-2 significantly promoted the amplification of γδ T cells. In addition,  γδ T cells showed the higher cytotoxicity against Daudi cells,  but no cytotoxic effect on normal cells like hFOB.
  
  
  CONCLUSIONS
  γδ T cells of high purity and high cytotoxicity can be obtained by the stimulation of Zol combined with IL-2 on PBMCs from healthy donors and osteosarcoma patients.
authors.affiliation: Department of Orthopaedics, Guilin Medical University, Guilin, China. lzxpds@126.com
authors.forename: Zhao-xu
authors.initials: ZX
authors.lastname: Li
authors.forename: Ling-ling
authors.initials: LL
authors.lastname: Sun
authors.forename: Rui-lin
authors.initials: RL
authors.lastname: Cheng
authors.forename: Zheng-wang
authors.initials: ZW
authors.lastname: Sun
authors.forename: Zhao-ming
authors.initials: ZM
authors.lastname: Ye
mesh_terms: D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000276:immunology* / Q000378:metabolism; D002478:Cells, Cultured; D004164:Diphosphonates / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D012516:Osteosarcoma / Q000276:immunology* / Q000378:metabolism; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D007376:Interleukin-2; D016692:Receptors, Antigen, T-Cell, gamma-delta; D000077211:Zoledronic Acid